Employees: 179
Size Puma Biotechnology (PBYI) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $373M, the 2895th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.22 on 18 Nov 2026.
Performance Over six months the shares gained 3.3%, against -25.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 9.3% over the last twelve months (peer median -6.5%); the operating margin is 11.3% (peer median -7.8%).
Valuation It trades at 19.0× forward earnings against a peer median of 24.5× (3rd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 36.2 points above its cost of capital (11.9% WACC).
Short interest Short interest is 8.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $232M | $228M | $230M | $236M | $228M |
| Revenue growth | — | -1% | -2% | +3% | — |
| Gross profit | $171M | $170M | $166M | $173M | $173M |
| EBITDA | $36.2M | $48.2M | $42.5M | $44.8M | $39.6M |
| Net income | $23.8M | $31.1M | $30.3M | $21.6M | $2,000 |
| Free cash flow | $46.1M | $41.7M | $38.9M | $26.9M | -$15.8M |
| Capital expenditure | -$36,000 | $71,000 | $56,000 | $12.6M | $0 |
| Total debt | $4.87M | $28.5M | $74.1M | $111M | $114M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBYI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.9% | -13.3% | 2nd lowest of 20 |
| 6-month return | +3.3% | -25.1% | 3rd highest of 19 |
| Distance from 52-week high | -37.2% | -43.3% | 10th highest of 21 |
| Revenue growth (TTM) | +9.3% | -6.5% | 4th highest of 18 |
| Operating margin | 11.3% | -7.8% | 4th highest of 19 |
| Forward P/E | 19.0× | 24.5× | 3rd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 0.1% | 5.1% | 3rd least demanding of 7 |
| Growth delivered (Del g) | +0.3% | +8.2% | 2nd lowest of 7 |
| Hurdle (Req g minus delivered) | -0.2 pp | -3.4 pp | 4th least demanding of 7 |
| ROIC minus cost of capital | +36.2 pp | -6.9 pp | highest of 17 |
| EV / EBITDA | 7.4× | 15.7× | cheapest of 6 |
| Net debt / EBITDA | -2.9× | 0.2× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 19.0× | 0.1% | +0.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | n/a | n/a | n/a |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | n/a | 22.2% | -15.7% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 398.3× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 8.2× | -7.9% | +24.8% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | n/a | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 13.6× | -5.5% | +12.2% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |